MLK
MLKs are a group of kinases that can activate multiple MAPK pathways, including JNK and p38, by phosphorylating upstream MAP kinase kinases (MAP2Ks). MLKs are involved in cellular responses to stress, apoptosis, and neuroinflammation. Dysregulation of MLK activity is associated with neurodegenerative diseases and certain cancers. At CymitQuimica, we offer a range of high-quality MLK modulators to support your research in neurobiology, stress response, and signal transduction.
Found 22 products of "MLK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
GW806742X
CAS:<p>GW806742X inhibits MLKL with Kd 9.3 μM, preventing necroptosis; also targets VEGFR2.</p>Formula:C25H22F3N7O4SPurity:98.3%Color and Shape:SolidMolecular weight:573.55Anticancer agent 267
<p>Anticanceragent 267 (Compound 5q) serves as an activator of RIPK3 and MLKL. It effectively inhibits the proliferation of several cancer cell lines, with IC50 values of 9.79, 10.77, and 5.94 μM for MDA-MB-231, MDA-MB-486, and MCF-7, respectively. The compound induces cell cycle arrest at the subG1 phase and triggers necroptosis in MDA-MB-231 cells. Additionally, Anticanceragent 267 demonstrates antitumor activity in mouse xenograft models.</p>Formula:C13H11N5O4SColor and Shape:SolidMolecular weight:333.32PROTAC MLKL Degrader-1
<p>PROTAC MLKL Degrader-1 (Compound 36) is a selective PROTAC degrader targeting MLKL, achieving a degradation maximum (D max) over 90%.</p>Formula:C46H55F2N9O9SColor and Shape:SolidMolecular weight:948.05MLKL-IN-2
CAS:<p>MLKL-IN-2 is an MLKL inhibitor with potential tumorigenic activity for the study of cellular necrosis-related diseases.</p>Formula:C26H25N5OPurity:98.30%Color and Shape:SolidMolecular weight:423.51KWCN-41
CAS:<p>KWCN-41, a RIPK1 inhibitor with 88 nM IC50, blocks necrosis, spares apoptosis, and is anti-inflammatory.</p>Formula:C18H17N3O2Color and Shape:SolidMolecular weight:307.35NecroX-2
CAS:<p>NecroX-2 is a cell-permeable necrosis inhibitor with antioxidant properties. NecroX-2 selectively suppresses necrotic cell death triggered by oxidative stress. NecroX-2 does not confer protection against apoptosis induced by staurosporine or etoposide but shows protective effects under conditions such as cold shock, hypoxia, and oxidative stress in vitro.</p>Formula:C25H32N4O4S2Purity:97.12%Color and Shape:SolidMolecular weight:516.68PROTAC MLKL Degrader-2
<p>PROTAC MLKL Degrader-2, a PROTAC that targets MLKL (Mixed Lineage Kinase), incorporates the PROTAC target protein ligand, E3 ligase ligand Thalidomide, and PROTAC Linker N-Methylpiperazine. The conjugate of the E3 ubiquitin ligase ligand and Linker is Thalidomide-N-Methylpiperazine. This compound exhibits antinecroptotic activity in human cell lines and effectively degrades MLKL in the HT-29 xenograft mouse model.</p>Formula:C36H35N9O9SColor and Shape:SolidMolecular weight:769.78RIPK3-IN-3
<p>RIPK3-IN-3 (compound 20) is a selective RIPK3 inhibitor that demonstrates potent activity with an IC50 value of 10 nM.</p>Formula:C16H11N5SColor and Shape:SolidMolecular weight:305.36MLKL-IN-7
<p>MLKL-IN-7 (compound 9) is an MLKL inhibitor that exhibits anti-necrotic activity in HT-29 cells, with an IC50 value of 148.4 nM.</p>Formula:C21H15N5O5S2Molecular weight:481.05146Necrosulfonamide
CAS:<p>Necrosulfonamide ((E)-Necrosulfonamide) is a necroptosis inhibitor that targets MLKL and is selective. High-Quality, Low-Cost!</p>Formula:C18H15N5O6S2Purity:98.85% - 99.49%Color and Shape:SolidMolecular weight:461.47LY-364947
CAS:<p>LY-364947 (HTS466284) is a potent ATP-competitive inhibitor of TGFβR-I.</p>Formula:C17H12N4Purity:99.41% - 99.96%Color and Shape:SolidMolecular weight:272.3AZ7550
CAS:<p>AZ7550, an active metabolite of AZD9291, inhibits the activity of IGF1R (IC50: 1.6 μM).</p>Formula:C27H31N7O2Purity:97.07% - 99.75%Color and Shape:SolidMolecular weight:485.58Cerdulatinib hydrochloride
CAS:<p>Cerdulatinib hydrochloride is an oral tyrosine kinase inhibitor targeting JAK1/2/3, TYK2, Syk, and 19 others with IC50 < 200 nM.</p>Formula:C20H28ClN7O3SPurity:99.85%Color and Shape:SolidMolecular weight:482SZM-1209
CAS:<p>SZM-1209 is a potent and specific RIPK1 inhibitor with oral activity, displaying a dissociation constant (Kd) of 85 nM.</p>Formula:C31H29F5N4O5S2Purity:98%Color and Shape:SolidMolecular weight:696.71MLKL-IN-5
CAS:<p>MLKL-IN-5 is a potent MLKL inhibitor that mediates necroptosis .</p>Formula:C18H20N6O4SColor and Shape:SolidMolecular weight:416.45IM-54
CAS:<p>IM-54 is a cell-permeable, effective, and selective necrosis inhibitor.</p>Formula:C19H23N3O2Purity:99.24%Color and Shape:SolidMolecular weight:325.4TC13172
CAS:<p>TC13172 is a potent, covalent MLKL inhibitor, selective over RIPK1/RIPK3. It blocks TSZ-induced necroptosis (EC50=2nM) and MLKL oligomerization at 100nM.</p>Formula:C17H16N4O5SPurity:98%Color and Shape:SolidMolecular weight:388.4MLKL-IN-1
<p>MLKL-IN-1 is a covalent inhibitor of MLKL with a Kd value of 50 μM.</p>Formula:C19H20N2O3Color and Shape:SolidMolecular weight:324.37MLKL-IN-6
<p>MLKL-IN-6 (compound P28) is a mixed lineage kinase inhibitor that specifically targets the Mixed Lineage Kinase domain-like (MLKL) protein.</p>Formula:C20H18N4O5Purity:98%Color and Shape:SolidMolecular weight:394.38Topoisomerase I/II inhibitor 8
CAS:<p>TopoisomeraseI/II inhibitor 8 (Compound Ru7) is a dual catalytic inhibitor of TopoisomeraseI/II that induces DNA damage and activates PARP-1, leading to the activation of RIPK1, RIPK3, and MLKL, ultimately causing necroptosis. It shows significant anticancer activity by effectively targeting cancer cell nuclei and inducing cell death through necroptosis, offering substantial clinical potential in overcoming resistance in cancer treatment.</p>Formula:C14H11Br2NO5S2Color and Shape:SolidMolecular weight:497.179
